CA
BPMC

Crewe Advisors’s Blueprint Medicines BPMC Stock Holding History

Crewe Advisors’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-50
Closed -$3K – 1052
2022
Q3 		$3K Hold
50
– – ﹤0.01% 941
2022
Q2 		$3K Buy
+50
New +$2.93K ﹤0.01% 868

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Crewe Advisors's BPMC Position: Q4 2022 in Review

Crewe Advisors sold out of Blueprint Medicines (BPMC) in Q4 2022, closing a stake of 50 shares — an estimated $3K sold.

Crewe Advisors first reported a position in BPMC in Q2 2022 and held it in 2 quarters. The position peaked at $3K in Q3 2022. 223 funds tracked by Wall St. Rank hold BPMC as of Q4 2022.

  • Crewe Advisors reported no remaining Blueprint Medicines position as of Q4 2022 after selling out during the quarter.
  • Crewe Advisors sold 50 Blueprint Medicines shares in Q4 2022, an estimated $3K.
  • Crewe Advisors first reported a position in Blueprint Medicines in Q2 2022 and held it in 2 quarters.
  • Crewe Advisors's Blueprint Medicines position peaked at $3K in Q3 2022.
  • 223 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2022.

Based on Crewe Advisors's 13F filing for Q4 2022, filed 8 Feb 2023.